# reload+after+2024-01-23 07:47:21.139668
address1§611 Gateway Boulevard
address2§Suite 740
city§South San Francisco
state§CA
zip§94080
country§United States
phone§415 655 4168
website§https://www.sprucebiosciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
fullTimeEmployees§31
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael G. Grey', 'age': 70, 'title': 'Executive Chairman', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 70000, 'exercisedValue': 0, 'unexercisedValue': 17020}, {'maxAge': 1, 'name': 'Dr. Javier  Szwarcberg M.D., M.P.H.', 'age': 53, 'title': 'CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 693900, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Samir M. Gharib CPA, M.B.A.', 'age': 41, 'title': 'President & CFO', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 536128, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ralph William Charlton III, M.D.', 'age': 53, 'title': 'Chief Medical Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 436379, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. P. J. Ramtin', 'title': 'Senior Vice President of Business Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Heidi  Petersen M.P.H.', 'title': 'Senior Vice President of Regulatory & Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.58
priceToSalesTrailing12Months§16.61892
currency§USD
dateShortInterest§1702598400
forwardEps§-1.45
exchange§NMS
quoteType§EQUITY
shortName§Spruce Biosciences, Inc.
longName§Spruce Biosciences, Inc.
firstTradeDateEpochUtc§1602250200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e400b3e3-c9c4-3efa-91e0-a411ff2f5c36
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§7.0
targetMeanPrice§8.33
targetMedianPrice§8.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§4.466
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
